
### **ARCUS OVERVIEW**

**NYSE: RCUS** 



Global, clinical-stage biopharmaceutical company at the forefront of designing novel combination therapies for cancer



#### HIGHLY PRODUCTIVE DRUG DISCOVERY

Small Molecules & Antibodies Designed to Be Combined

PD-1, CD39



Targets: CD73, HIF-2a, A2a/2b, AXL



new molecules advancing into clinic each year




Accelerated
P 1/2 signalseeking &
platform studies


#### **DIVERSE PIPELINE & KEY DATA FOR 2025+**


7

Different molecules in clinic St Pivotal Readout



3+ HIF-2a Cas Events





 Planned initiation of Phase 3 cas + cabo study \$10B+



Addressable market opportunity in the U.S. based on expected drug treatable patient population

#### **TOP-TIER PARTNERS FOR STRATEGIC & CLINICAL COLLABORATIONS**



Learn more at

Funding:

~\$1.7B

- Holds ~30% equity stake in Arcus
- 50/50 Cost-sharing for certain optioned programs
- Co-development / co-commercialization in the U.S.

TAIHO PHARMA



## STRONG FINANCIAL POSITION & CASH RUNWAY WITH FUNDING THROUGH MULTIPLE PHASE 3 READOUTS



~\$1B cash, cash equivalents & marketable securities as of 12/31/2024

# HQ & RESEARCH CAMPUSES IN BAY AREA



~600

employees



Except as stated otherwise, this summary is provided as of 2/25/2025. Cash, cash equivalents & marketable securities excludes \$150 million financing announced in February 2025. For a more complete description of our business and risks and uncertainties that may affect forward-looking statements made in this summary, including the statement regarding funding through multiple Phase 3 readouts, please refer to our full corporate presentation and latest Form 10-K and Form 10-Q, which can be found at investors.arcusbio.com.